Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV003071935 | SCV003459660 | uncertain significance | Bloom syndrome | 2022-07-29 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. This variant has not been reported in the literature in individuals affected with BLM-related conditions. This variant is present in population databases (rs758753168, gnomAD 0.006%). This sequence change replaces serine, which is neutral and polar, with asparagine, which is neutral and polar, at codon 1121 of the BLM protein (p.Ser1121Asn). |
Ambry Genetics | RCV004948956 | SCV005544567 | uncertain significance | Hereditary cancer-predisposing syndrome | 2024-10-08 | criteria provided, single submitter | clinical testing | The p.S1121N variant (also known as c.3362G>A), located in coding exon 17 of the BLM gene, results from a G to A substitution at nucleotide position 3362. The serine at codon 1121 is replaced by asparagine, an amino acid with highly similar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Based on the available evidence, the clinical significance of this variant remains unclear. |